Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin
Status:
Withdrawn
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
iTRAP is an open-label, multi-centre, dose escalation study of ADI PEG20 in combination with
atezolizumab, pemetrexed and carboplatin in patients with advanced non-squamous non-small
cell lung carcinoma (NSCLC) - stage IIIB/IV.